<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35272573</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov.</ArticleTitle>
        <Pagination>
          <StartPage>461</StartPage>
          <EndPage>472</EndPage>
          <MedlinePgn>461-472</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2048017</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">IgA Nephropathy (IgAN) is common chronic kidney disease with a high incidence. This study aims to analyze comprehensively therapeutic clinical trials for IgAN registered on ClinicalTrials.gov.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Therapeutic trials for IgAN registered on ClinicalTrials.gov. up to 15 August 2021 were obtained. The general characteristics, features of experimental design, treatment strategies, and some main inclusion criteria and outcome measures were accessed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 104 therapeutic clinical trials for IgAN were extracted on ClinicalTrials.gov up to 15 August 2021. Most of these trials explored the treatment for primary IgAN confirmed by renal biopsy in adults. Only 9% of all selected trials had results. Forty-five percent of trials recruited 50 or fewer participants, and 73% were adults or older adults. 99% of trials were interventional studies, and of all the interventional trials, 70% of trials were randomized, and 68% exercised a parallel assignment of intervention model. Immunosuppression was the most studied for the treatment of IgAN. Moreover, many novel agents had been increasingly studied in recent years. Furthermore, the inclusion criteria and primary outcome measures in these trials were diverse, and the level of proteinuria and change of proteinuria levels were the most used as inclusion criteria and primary outcome, respectively.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The majority of therapeutic trials for IgAN were randomized, none masking and parallel-assignment interventional studies, primarily recruiting adult patients as research subjects. These trials had relatively small sample sizes and short observation. Thus, more large-scale, multicenter, and randomized controlled trials are still needed to improve the management for IgAN.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhai</LastName>
            <ForeName>Ya-Ling</ForeName>
            <Initials>YL</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Yuan-Yuan</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xin-Ran</ForeName>
            <Initials>XR</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Ya-Fei</ForeName>
            <Initials>YF</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Fu</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Li-Pei</ForeName>
            <Initials>LP</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Zhan-Zheng</ForeName>
            <Initials>ZZ</Initials>
            <AffiliationInfo>
              <Affiliation>Nephrology Hospital, The First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
          <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032882" MajorTopicYN="N">Comprehension</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005922" MajorTopicYN="N">Glomerulonephritis, IGA</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
          <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ClinicalTrials.gov</Keyword>
        <Keyword MajorTopicYN="N">IgA nephropathy</Keyword>
        <Keyword MajorTopicYN="N">clinical trials</Keyword>
        <Keyword MajorTopicYN="N">treatment</Keyword>
      </KeywordList>
      <CoiStatement>The authors declared no conflicts of interest in this study.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35272573</ArticleId>
        <ArticleId IdType="pmc">PMC8920363</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2048017</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Rajasekaran A, Julian BA, Rizk DV.. 
IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8577278</ArticleId>
            <ArticleId IdType="pubmed">33309134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selvaskandan H, Cheung CK, Muto M, et al. . 
New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol. 2019;23(5):577–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6469670</ArticleId>
            <ArticleId IdType="pubmed">30756248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagchi S, Mani K, Swamy A, et al. . 
Supportive management of IgA nephropathy with Renin-Angiotensin blockade, the AIIMS primary IgA nephropathy cohort (APPROACH) study. Kidney Int Rep. 2021;6(6):1661–1668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8207308</ArticleId>
            <ArticleId IdType="pubmed">34169207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung CK, Barratt J.. 
Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial. Kidney Int. 2020;98(4):836–838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32998815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrigues JC, Haas M, Reich HN.. 
IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5383386</ArticleId>
            <ArticleId IdType="pubmed">28159829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Amico G.
Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24(3):179–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15156525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyatt RJ, Julian BA.. 
IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23782179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch BR, Califf RM, Cheng SK, et al. . 
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med. 2013;173(11):972–979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23699837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y, Wang Y, Li R, et al. . 
Comprehensive analysis of clinical trials registration for lupus nephritis therapy on ClinicalTrials.gov. Front Med. 2021;8:680302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8248800</ArticleId>
            <ArticleId IdType="pubmed">34222288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long J, Liang R, Zheng Q, et al. . 
Overview of clinical trials on type 2 diabetes mellitus: a comprehensive analysis of the ClinicalTrials.gov database. Diabetes Metab Syndr Obes. 2021;14:367–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7847376</ArticleId>
            <ArticleId IdType="pubmed">33531823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang YB, Lv G, Xu FH, et al. . 
Comprehensive survey of clinical trials registration for melanoma immunotherapy in the ClinicalTrials.gov. Front Pharmacol. 2020;10:1539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6966167</ArticleId>
            <ArticleId IdType="pubmed">31998135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lafayette RA, Canetta PA, Rovin BH, et al. . 
A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. JASN. 2017;28(4):1306–1313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5373458</ArticleId>
            <ArticleId IdType="pubmed">27821627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y, Chen W, Jalal D, et al. . 
Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3242707</ArticleId>
            <ArticleId IdType="pubmed">22116196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartono C, Chung M, Perlman AS, et al. . 
Bortezomib for reduction of proteinuria in IgA nephropathy. Kidney Int Rep. 2018;3(4):861–866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6035125</ArticleId>
            <ArticleId IdType="pubmed">29988921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bomback AS, Canetta PA, Beck LH Jr., et al. . 
Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36(1):58–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22722778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Angelis C, Drazen JM, Frizelle FA, et al. . 
Clinical trial registration: a statement from the international committee of medical journal editors. Lancet. 2004;364(9438):911–912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15364170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassler JR.
IgA nephropathy: a brief review. Semin Diagn Pathol. 2020;37(3):143–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32241578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kahan BC, Harhay MO.. 
Many multicenter trials had few events per center, requiring analysis via random-effects models or GEEs. J Clin Epidemiol. 2015;68(12):1504–1511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4845666</ArticleId>
            <ArticleId IdType="pubmed">25985892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppo R, Robert T.. 
IgA nephropathy in children and in adults: two separate entities or the same disease?
J Nephrol. 2020;33(6):1219–1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32314305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gluud LL.
Bias in clinical intervention research. Am J Epidemiol. 2006;163(6):493–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16443796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood L, Egger M, Gluud LL, et al. . 
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2267990</ArticleId>
            <ArticleId IdType="pubmed">18316340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taichman DB, Sahni P, Pinborg A, et al. . 
Data sharing statements for clinical trials: a requirement of the international committee of medical journal editors. PLOS Med. 2017;14(6):e1002315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5459581</ArticleId>
            <ArticleId IdType="pubmed">28582414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pozzi C.
Treatment of IgA nephropathy. J Nephrol. 2016;29(1):21–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26577268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group . KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34556256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Xu G.. 
An update on targeted treatment of IgA nephropathy: an autoimmune perspective. Front Pharmacol. 2021;12:715253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8419281</ArticleId>
            <ArticleId IdType="pubmed">34497518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tortajada A, Gutierrez E, Pickering MC, et al. . 
The role of complement in IgA nephropathy. Mol Immunol. 2019;114:123–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31351413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maillard N, Wyatt RJ, Julian BA, et al. . 
Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26(7):1503–1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4483595</ArticleId>
            <ArticleId IdType="pubmed">25694468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Stang MB, Gleeson PJ, Daha MR, et al. . 
Is complement the main accomplice in IgA nephropathy? From initial observations to potential complement-targeted therapies. Mol Immunol. 2021;140:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34601376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roos A, Rastaldi MP, Calvaresi N, et al. . 
Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17(6):1724–1734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16687629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reich HN, Troyanov S, Scholey JW, et al. . 
Remission of proteinuria improves prognosis in IgA nephropathy. JASN. 2007;18(12):3177–3183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17978307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berthoux F, Mohey H, Laurent B, et al. . 
Predicting the risk for dialysis or death in IgA nephropathy. JASN. 2011;22(4):752–761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3065230</ArticleId>
            <ArticleId IdType="pubmed">21258035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maixnerova D, Reily C, Bian Q, et al. . 
Markers for the progression of IgA nephropathy. J Nephrol. 2016;29(4):535–541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5548426</ArticleId>
            <ArticleId IdType="pubmed">27142988</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
